Adult Dosing
Enterocolitis caused by Staphylococcus aureus
- 0.5-2 g/day PO divided tid-qid x 7-10 days
C. difficile-associated diarrhea
- 0.5-2 g/day PO divided tid-qid x 7-10 days
Pediatric Dosing
Enterocolitis caused by Staphylococcus aureus
- 40 mg/kg/day PO divided tid-qid x 7-10 days
- Max: 500 mg/dose, 2 g/day
C. difficile-associated diarrhea
- 40 mg/kg/day PO divided tid-qid x 7-10 days
- Max: 500 mg/dose, 2 g/day
[Outline]
Renal Dose Adjustment (Based on CrCl)
- Detectable serum levels may occur in renal impairment. Monitor levels and adjust dose/interval
Hepatic Dose Adjustment
- Hepatic impairment: Dose adjustments not defined
- Administer only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria
- Significant systemic absorption occurs in inflammatory disorders of the intestinal mucosa. Increased risk of adverse reactions associated with the parenteral administration of vancomycin (see package insert), more commonly if renal impairment
- Prolonged use increases risk of bacterial superinfection; institute appropriate therapy if superinfection occurs
- May cause transient/permanent ototoxicity, more commonly in patients given excessive doses, hearing impairment, concurrent aminoglycosides/ototoxic agents
- Reversible neutropenia has been reported in patients receiving vancomycin
- Monitor Cr at baseline, continue periodically if renal impairment or concomitant aminoglycosides
- Monitor WBC if prolonged therapy
- Monitor serum drug levels in renal impairment, neonates, infants, elderly
- Consider serial audiometry especially if concurrent aminoglycosides/ototoxic agents
Cautions: Use cautiously in
- Intestinal obstruction or inflammation (increased systemic absorption when given orally)
- Renal impairment (refer dose adjustment section)
- Hearing impairment
- Concurrent nephrotoxic agents
- Concurrent ototoxic agents
- Inflammatory bowel disorders
- Neonates
- Lactation
- Elderly patients
Pregnancy Category:B
Breastfeeding: Limited information; however, minimal systemic absorption, may have minimal excretion in breast milk. Vancomycin would not be expected to cause any adverse effects in breastfed infants. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 6 September 2010).
Pricing data from www.DrugStore.com in U.S.A.
- Vancocin HCl 250 MG CAPS [Box] (VIROPHARMA )
INC mg = $20
mg = $60 - Vancocin HCl 125 MG CAPS [Box] (VIROPHARMA )
INC mg = $20
mg = $60
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
